Cellcolabs Clinical SPV
CompanySweden
Cellcolabs Clinical SPV develops 2 assets, the furthest in phase 2 (mesenchymal stem cells in COVID-19 pneumonia). Mostly cell therapy acting on inflammation and stem cell maintenance; based in Sweden.
- Assets
- 2
- Furthest
- Phase 2
- Trials
- 3
- Signals
- 0
Pipeline
2Umbilical cord-derived mesenchymal stem cells for tissue repair and immunomodulation
Phase 2Cell therapyInflammationStem cell maintenanceCOVID-19 pneumoniaHuntington's disease
Allogeneic bone marrow-derived mesenchymal stromal cells for the prevention of cardiovascular events
Phase 1Cell therapyInflammationStem cell maintenanceaging frailtycardiovascular disease
Full company profiles: pipeline, trials, funding and people.
See Pro- Evidence behind the mechanisms3
- Trials3
- Signals2
- Similar companies6
Updated 7 Oct 2026 · 35 sources